Skip to main content Skip to search Skip to main navigation

MHRA: Alignment With EU on Extention of GMP and GDP Certificates

On 11 December, the UK Medicines and Healthcare Products Regulatory Agency (MHRA) announced a validity extension of GMP and GDP certificates.

With the announcement of the return of international on-site inspections in November 2022, the authority announced an extension of the validity of GMP and GDP certificates until the end of 2023. As many of the inspections postponed during the COVID-19 pandemic have yet to be carried out, the MHRA has aligned with the EU regulations on the extension of validity. Their blog post states "The MHRA has decided (in consultation with our international partners) to continue the extension of the validity date until 2024 or until the completion of the next inspection, whichever comes first, unless otherwise stated on the certificate."

Inspections will continue to be prioritised based on risk so that manufacturers and wholesalers with the highest priority will be inspected first. In addition, inspections will be prioritised if the GMP or GDP certificate is already five years or older.


Source:

MHRA: GMP & GDP Certificates: Validity Period Extended

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be Interested in the Following Articles:

What is a gas?

What is a gas?

You can view the answer here:
Read more
EDQM: New Ph. Eur. Chapter on Data Quality with a Focus on Digital Data

EDQM: New Ph. Eur. Chapter on Data Quality with a Focus on Digital Data

The European Pharmacopoeia (Ph. Eur.) has introduced a new general chapter that provides a framework for managing the quality of data, including digital data, throughout its life cycle.

Read more
EMA: Pilot Programme for Breakthrough Devices

EMA: Pilot Programme for Breakthrough Devices

The EMA plans to launch a pilot programme in Q2 2026 to implement the guidance for breakthrough devices issued in December 2025.

Read more
PIC/S: Jordan FDA Joins PIC/S

PIC/S: Jordan FDA Joins PIC/S

On 1 January 2026, the Jordan Food & Drug Administration (JFDA) became the 57th PIC/S Participating Authority.

Read more
Swissmedic: Scientific GMDP Meetings

Swissmedic: Scientific GMDP Meetings

Swissmedic offers companies holding or seeking a Swissmedic manufacturing or distribution license the opportunity to discuss project-specific GMP and GDP topics in Scientific GMDP Meetings.

Read more
Purified Water – The new Chinese Pharmacopoeias and What Happens Next?

Purified Water – The new Chinese Pharmacopoeias and What Happens Next?

A new Chinese Pharmacopoeia was published in 2025. This has some significant implications for the pharmaceutical water industry, which we will discuss in more detail in this article. Firstly, it is important to note that cold WFI systems are now permitted worldwide and can be used across the board.
Read more
Previous
Next